Keynote address by Myriam Chalabi at ESMOGI24

Toni Choueiri shared on X:

“Keynote address at ESMOGI24 with superstar Myriam Chalabi– Immunotherapy for MSS-CRC: The last frontier.”

Source: Toni Choueiri/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.

Dr. Myriam Chalabi, a medical oncologist and researcher based at the Netherlands Cancer Institute, specializes in gastrointestinal tract cancer. Her research primarily focuses on immunotherapy for gastrointestinal cancers.

In 2017, she initiated a clinical investigation called the NICHE trial, aiming to explore the potential benefits of immunotherapy for early-stage colon cancer patients.

Through this trial, Dr. Chalabi identified a subtype of colon cancer patients deficient in mismatch repair, exhibiting DNA replication errors, who demonstrate remarkable responsiveness to immunotherapy. She possesses expertise in neoadjuvant immunotherapies for these specific indications.

Additionally, Dr. Chalabi underscores the significance of biomarkers in patient selection for immuno-oncology clinical trials.